Cellectis S.A. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K report, dated March 29, 2021, concerns Cellectis S.A., a foreign private issuer headquartered in Paris, France. The filing discloses the execution of a new equity distribution agreement rather than reporting periodic financial results.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The primary financial figure disclosed is the aggregate offering price of up to $125.0 million for American Depositary Shares (ADSs) under a new sales program.
Material Changes and Transactions
On March 29, 2021, Cellectis S.A. entered into a Sales Agreement with Jefferies LLC to establish an "at-the-market" equity offering program. Key terms include:
- Offering Size: Up to $125.0 million in aggregate gross proceeds.
- Agent: Jefferies LLC will act as the sales agent.
- Commission: The Company will pay Jefferies a commission of 3.0% of the gross sales price per ADS sold.
- Structure: Sales may be made in "at-the-market" offerings or negotiated transactions. Jefferies is not obligated to sell a specific amount of securities.
- Termination: Either party may terminate the agreement with ten trading days' prior notice.
Outlook, Risks, and Management Commentary
The filing indicates that the Company is not obligated to make any sales of ADSs under the agreement. The offering will terminate upon the sale of all ADSs subject to the agreement or earlier termination. The text notes that the Company has agreed to provide indemnification and contribution to Jefferies regarding certain liabilities under the Securities Act and the Securities Exchange Act of 1934. No specific forward-looking guidance or risk factors beyond the standard legal disclosures for the offering were detailed in this summary text.
Key Facts for Investor Verification
- Verify the current market price of Cellectis ADSs to assess the potential dilution impact of a $125.0 million offering.
- Confirm the Company's current cash position and burn rate to understand the necessity of this capital raise.
- Review the full Sales Agreement (Exhibit 1.1) for specific conditions regarding the timing and volume of sales.
- Monitor subsequent filings to determine if and when the Company elects to sell shares under this program.